News LEO Pharma teams up with Wearifi for dermatology research we... LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development.
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.